BRPI0716092A2 - composto ou um sal, solvato, ou estereoisâmero do mesmo, composiÇço farmacÊutica, mÉtodo para tratar, controlar ou prevenir uma doenÇa ou distérbio, e, forma de dosagem de unidade simples. - Google Patents

composto ou um sal, solvato, ou estereoisâmero do mesmo, composiÇço farmacÊutica, mÉtodo para tratar, controlar ou prevenir uma doenÇa ou distérbio, e, forma de dosagem de unidade simples.

Info

Publication number: BRPI0716092A2
Authority: BR; Brazil
Prior art keywords: stereoisomer; solvate; disorder; disease; treating
Prior art date: 2006-08-30

Application number

BRPI0716092-5A2A

Other languages

English (en)

Inventor

George W Muller

Roger S C Chen

Alexandre L Ruchelman

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-30

Filing date

2007-08-29

Publication date

2013-09-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38996198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0716092(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-08-29 Application filed by Celgene Corp filed Critical Celgene Corp

2013-09-17 Publication of BRPI0716092A2 publication Critical patent/BRPI0716092A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Immunology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Anesthesiology (AREA)
Tropical Medicine & Parasitology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0716092-5A2A 2006-08-30 2007-08-29 composto ou um sal, solvato, ou estereoisâmero do mesmo, composiÇço farmacÊutica, mÉtodo para tratar, controlar ou prevenir uma doenÇa ou distérbio, e, forma de dosagem de unidade simples. BRPI0716092A2 (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US84136506P	2006-08-30	2006-08-30
US92551307P	2007-04-20	2007-04-20
US93778207P	2007-06-28	2007-06-28
PCT/US2007/019182 WO2008027542A2 (en)	2006-08-30	2007-08-29	5-substituted isoindoline compounds

Publications (1)

Publication Number	Publication Date
BRPI0716092A2 true BRPI0716092A2 (pt)	2013-09-17

Family

ID=38996198

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0716092-5A2A BRPI0716092A2 (pt)	2006-08-30	2007-08-29	composto ou um sal, solvato, ou estereoisâmero do mesmo, composiÇço farmacÊutica, mÉtodo para tratar, controlar ou prevenir uma doenÇa ou distérbio, e, forma de dosagem de unidade simples.

Country Status (17)

Country	Link
EP (1)	EP2057143B1 (pt)
JP (2)	JP5523831B2 (pt)
KR (1)	KR20090060314A (pt)
AR (1)	AR062606A1 (pt)
AU (1)	AU2007290407A1 (pt)
BR (1)	BRPI0716092A2 (pt)
CA (1)	CA2660806C (pt)
CL (1)	CL2007002513A1 (pt)
CO (1)	CO6160231A2 (pt)
CR (1)	CR10653A (pt)
ES (1)	ES2426350T3 (pt)
IL (1)	IL197098A0 (pt)
MX (1)	MX2009001989A (pt)
NZ (1)	NZ575061A (pt)
PE (1)	PE20080768A1 (pt)
TW (1)	TW200817368A (pt)
WO (1)	WO2008027542A2 (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CL2007002499A1 (es)	2006-08-30	2008-03-14	Phenomix Corp	Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
US8877780B2 (en) *	2006-08-30	2014-11-04	Celgene Corporation	5-substituted isoindoline compounds
CA2660806C (en) *	2006-08-30	2015-06-16	Celgene Corporation	5-substituted isoindoline compounds
RU2527952C2 (ru) *	2008-10-29	2014-09-10	Селджин Корпорейшн	Изоиндолиновые соединения для применения при лечении рака
EP2699091B1 (en)	2011-03-28	2017-06-21	DeuteRx, LLC	2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
CA2935495C (en)	2013-01-14	2021-04-20	Deuterx, Llc	3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
AU2014236597A1 (en)	2013-03-14	2015-09-24	Deuterx, Llc	3-(substituted-4-oxo-quinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives
UA117141C2 (uk)	2013-10-08	2018-06-25	Селджин Корпорейшн	Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
MX2016007239A (es)	2013-12-06	2017-01-05	Celgene Corp	Metodos para determinar la eficacia del farmaco para el tratamiento de linfoma difuso de celulas b grandes, mieloma multiple, y canceres mieloides.
KR20210132233A (ko) *	2014-04-14	2021-11-03	아비나스 오퍼레이션스, 인코포레이티드	단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
US9499514B2 (en) *	2014-07-11	2016-11-22	Celgene Corporation	Antiproliferative compounds and methods of use thereof
US20180267043A1 (en) *	2014-10-07	2018-09-20	Celgene Corporation	Use of biomarkers for predicting clinical sensitivity to cancer treatment
JP6815318B2 (ja) *	2014-12-23	2021-01-20	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	二官能性分子によって標的化タンパク質分解を誘導する方法
US9694084B2 (en)	2014-12-23	2017-07-04	Dana-Farber Cancer Institute, Inc.	Methods to induce targeted protein degradation through bifunctional molecules
US20170327469A1 (en)	2015-01-20	2017-11-16	Arvinas, Inc.	Compounds and methods for the targeted degradation of androgen receptor
KR20200052995A (ko)	2015-01-20	2020-05-15	아비나스 오퍼레이션스, 인코포레이티드	안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
EP3302482A4 (en)	2015-06-05	2018-12-19	Arvinas, Inc.	Tank-binding kinase-1 protacs and associated methods of use
US9809603B1 (en)	2015-08-18	2017-11-07	Deuterx, Llc	Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
EP3337476A4 (en)	2015-08-19	2019-09-04	Arvinas, Inc.	COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS CONTAINING BROMODOMAIN
RS61070B1 (sr) *	2016-01-08	2020-12-31	Celgene Corp	Antiproliferativna jedinjenja i njihove farmaceutske kompozicije i upotrebe
US10759808B2 (en) *	2016-04-06	2020-09-01	The Regents Of The University Of Michigan	Monofunctional intermediates for ligand-dependent target protein degradation
WO2017197051A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	Amine-linked c3-glutarimide degronimers for target protein degradation
EP3454862B1 (en)	2016-05-10	2024-09-11	C4 Therapeutics, Inc.	Spirocyclic degronimers for target protein degradation
EP3454856B1 (en)	2016-05-10	2024-09-11	C4 Therapeutics, Inc.	Heterocyclic degronimers for target protein degradation
CN109641874A (zh)	2016-05-10	2019-04-16	C4医药公司	用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
SI3660004T1 (sl)	2016-10-11	2023-08-31	Arvinas Operations, Inc.	Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
WO2018102067A2 (en)	2016-11-01	2018-06-07	Arvinas, Inc.	Tau-protein targeting protacs and associated methods of use
PT3689868T (pt)	2016-12-01	2024-01-02	Arvinas Operations Inc	Derivados de tetra-hidronaftaleno e tetrahidroisoquinolina como degradadores do recetor de estrogénio
US11173211B2 (en)	2016-12-23	2021-11-16	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
WO2018119448A1 (en)	2016-12-23	2018-06-28	Arvinas, Inc.	Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
CA3047586A1 (en)	2016-12-23	2018-06-28	Arvinas Operations, Inc.	Egfr proteolysis targeting chimeric molecules and associated methods of use
WO2018118598A1 (en)	2016-12-23	2018-06-28	Arvinas, Inc.	Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11191741B2 (en)	2016-12-24	2021-12-07	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
JP7266526B6 (ja)	2017-01-26	2024-02-15	アルビナス・オペレーションズ・インコーポレイテッド	エストロゲン受容体タンパク質分解性の調節因子およびその関連方法
WO2018237026A1 (en)	2017-06-20	2018-12-27	C4 Therapeutics, Inc.	N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
CN118108706A (zh)	2017-09-04	2024-05-31	C4医药公司	戊二酰亚胺
CN118206529A (zh)	2017-09-04	2024-06-18	C4医药公司	二氢苯并咪唑酮
WO2019043208A1 (en)	2017-09-04	2019-03-07	F. Hoffmann-La Roche Ag	DIHYDROQUINOLINONES
CN111372585A (zh)	2017-11-16	2020-07-03	C4医药公司	用于靶蛋白降解的降解剂和降解决定子
EP3710443A1 (en)	2017-11-17	2020-09-23	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
US11220515B2 (en)	2018-01-26	2022-01-11	Yale University	Imide-based modulators of proteolysis and associated methods of use
EP3773576A4 (en)	2018-03-26	2021-12-29	C4 Therapeutics, Inc.	Cereblon binders for the degradation of ikaros
EP3774777A2 (en)	2018-04-04	2021-02-17	Arvinas Operations, Inc.	Modulators of proteolysis and associated methods of use
EP3781156A4 (en)	2018-04-16	2022-05-18	C4 Therapeutics, Inc.	SPIROCYCLIC COMPOUNDS
FI3784663T3 (fi)	2018-04-23	2023-10-06	Celgene Corp	Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi
EP3578561A1 (en)	2018-06-04	2019-12-11	F. Hoffmann-La Roche AG	Spiro compounds
CN112912376A (zh)	2018-08-20	2021-06-04	阿尔维纳斯运营股份有限公司	用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
AU2019348094B2 (en)	2018-09-30	2022-12-22	Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences	Isoindoline compound, preparation method, pharmaceutical composition and use thereof
EP3880669A1 (en)	2018-11-13	2021-09-22	Biotheryx, Inc.	Substituted isoindolinones
CN111285850B (zh)	2018-12-06	2022-04-22	中国科学院上海药物研究所	一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
KR20210152515A (ko)	2019-04-12	2021-12-15	씨4 테라퓨틱스, 인코포레이티드	이카로스 및 아이올로스의 트리시클릭 분해제
KR20220016167A (ko)	2019-05-31	2022-02-08	셀진 코포레이션	치환된 1-옥소-이소인돌린-5-카르복스아미드 화합물, 그의 조성물 및 그를 사용한 치료 방법
US11912699B2 (en)	2019-07-17	2024-02-27	Arvinas Operations, Inc.	Tau-protein targeting compounds and associated
JP2022551185A (ja) *	2019-10-09	2022-12-07	モンテローザセラピューティクスアーゲー	イソインドリノン化合物
JP2023504445A (ja)	2019-11-27	2023-02-03	キャプターセラピューティクスエス．エー．	セレブロンに結合するピペリジン－２，６－ジオン誘導体、及びその使用方法
EP4065576A1 (en)	2019-11-27	2022-10-05	Captor Therapeutics S.A.	Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
BR112022012110A2 (pt)	2019-12-19	2022-12-13	Arvinas Operations Inc	Compostos e métodos para a degradação direcionada de receptor androgênico
CN115996918A (zh)	2020-05-09	2023-04-21	阿尔维纳斯运营股份有限公司	制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
AU2021319847A1 (en) *	2020-08-03	2023-03-02	Captor Therapeutics S.A.	Low molecular weight protein degraders and their applications
AU2021347238A1 (en) *	2020-09-23	2023-06-01	St. Jude Children's Research Hospital, Inc.	Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
WO2022146151A1 (en)	2020-12-30	2022-07-07	Captor Therapeutics S.A.	Novel compounds which bind to cereblon, and methods of use thereof
AU2022207648A1 (en)	2021-01-13	2023-07-27	Monte Rosa Therapeutics Ag	Isoindolinone compounds
EP4313047A1 (en) *	2021-03-22	2024-02-07	Monte Rosa Therapeutics, Inc.	Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons
AU2022259683A1 (en)	2021-04-16	2023-10-19	Arvinas Operations, Inc.	Modulators of bcl6 proteolysis and associated methods of use
WO2022255889A1 (en)	2021-06-01	2022-12-08	Captor Therapeutics S.A.	Compounds which bind to cereblon, and use thereof
WO2022255890A1 (en)	2021-06-01	2022-12-08	Captor Therapeutics S.A.	Compounds which bind to cereblon, and use thereof
WO2024015618A2 (en) *	2022-07-15	2024-01-18	St. Jude Children's Research Hospital, Inc.	Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione/2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione analogs as modulators of cereblon protein
WO2024054591A1 (en)	2022-09-07	2024-03-14	Arvinas Operations, Inc.	Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
KR20240066904A (ko) *	2022-11-08	2024-05-16	주식회사 온코드바이오	아릴시클로알킬아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도
WO2024167423A1 (en)	2023-02-07	2024-08-15	Captor Therapeutics S.A.	Gspt1 degrader compounds
KR102570883B1 (ko) *	2023-04-13	2023-08-29	(주) 사이러스테라퓨틱스	신규한 gspt1 분해제 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5635517B1 (en) *	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) *	1996-07-24	2013-05-28	Celgene Corp	Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
EP2070920B8 (en) *	1996-07-24	2011-04-27	Celgene Corporation	Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels
US5955476A (en) *	1997-11-18	1999-09-21	Celgene Corporation	Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
JP2000159761A (ja) *	1998-11-30	2000-06-13	Yoshio Takeuchi	フルオロサリドマイド
US20030045552A1 (en) *	2000-12-27	2003-03-06	Robarge Michael J.	Isoindole-imide compounds, compositions, and uses thereof
US7323479B2 (en) *	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
CN1867331B (zh) *	2003-09-17	2010-05-26	美国政府健康及人类服务部	作为TNF-α调节剂的沙利度胺类似物
US8877780B2 (en) *	2006-08-30	2014-11-04	Celgene Corporation	5-substituted isoindoline compounds
CA2660806C (en) *	2006-08-30	2015-06-16	Celgene Corporation	5-substituted isoindoline compounds

2007
- 2007-08-29 CA CA2660806A patent/CA2660806C/en active Active
- 2007-08-29 WO PCT/US2007/019182 patent/WO2008027542A2/en active Application Filing
- 2007-08-29 KR KR1020097006325A patent/KR20090060314A/ko not_active Application Discontinuation
- 2007-08-29 NZ NZ575061A patent/NZ575061A/en not_active IP Right Cessation
- 2007-08-29 EP EP07837606.8A patent/EP2057143B1/en active Active
- 2007-08-29 BR BRPI0716092-5A2A patent/BRPI0716092A2/pt not_active IP Right Cessation
- 2007-08-29 ES ES07837606T patent/ES2426350T3/es active Active
- 2007-08-29 JP JP2009526742A patent/JP5523831B2/ja active Active
- 2007-08-29 AU AU2007290407A patent/AU2007290407A1/en not_active Abandoned
- 2007-08-29 MX MX2009001989A patent/MX2009001989A/es active IP Right Grant
- 2007-08-29 CL CL200702513A patent/CL2007002513A1/es unknown
- 2007-08-30 AR ARP070103860A patent/AR062606A1/es unknown
- 2007-08-30 TW TW096132346A patent/TW200817368A/zh unknown
- 2007-09-03 PE PE2007001182A patent/PE20080768A1/es not_active Application Discontinuation
2009
- 2009-02-17 IL IL197098A patent/IL197098A0/en unknown
- 2009-03-05 CR CR10653A patent/CR10653A/es not_active Application Discontinuation
- 2009-03-17 CO CO09027212A patent/CO6160231A2/es unknown
2014
- 2014-04-09 JP JP2014079842A patent/JP5853047B2/ja active Active

Also Published As

Publication number	Publication date
EP2057143B1 (en)	2013-07-24
WO2008027542A2 (en)	2008-03-06
KR20090060314A (ko)	2009-06-11
CA2660806A1 (en)	2008-03-06
IL197098A0 (en)	2009-11-18
ES2426350T3 (es)	2013-10-22
CA2660806C (en)	2015-06-16
CL2007002513A1 (es)	2008-04-04
CO6160231A2 (es)	2010-05-20
AR062606A1 (es)	2008-11-19
JP2014141521A (ja)	2014-08-07
JP5853047B2 (ja)	2016-02-09
JP5523831B2 (ja)	2014-06-18
EP2057143A2 (en)	2009-05-13
NZ575061A (en)	2011-10-28
AU2007290407A1 (en)	2008-03-06
TW200817368A (en)	2008-04-16
PE20080768A1 (es)	2008-06-14
MX2009001989A (es)	2009-03-09
JP2010502627A (ja)	2010-01-28
CR10653A (es)	2009-04-03
WO2008027542A3 (en)	2008-04-17

Publication	Publication Date	Title
BRPI0716092A2 (pt)	2013-09-17	composto ou um sal, solvato, ou estereoisâmero do mesmo, composiÇço farmacÊutica, mÉtodo para tratar, controlar ou prevenir uma doenÇa ou distérbio, e, forma de dosagem de unidade simples.
BRPI0912111A2 (pt)	2015-10-06	composto, composição farmacêutica, método para tratar, controlar ou prevenir uma doença ou distúrbio, e, forma de dosagem unitária única
BRPI0915382A2 (pt)	2017-06-27	composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BR112012004333A2 (pt)	2015-09-08	composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BRPI0815708A2 (pt)	2014-09-30	Composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição.
BRPI0821274A2 (pt)	2017-06-13	composto ou um sal, ou pró-droga farmaceuticamente aceitável do mesmo, uso do mesmo, método para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
BRPI0909768A2 (pt)	2015-10-06	composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
BRPI0822398A2 (pt)	2014-11-18	Forma sólida, mistura, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou distúrbio e um câncer
BRPI0917705A2 (pt)	2016-02-16	composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0819802A2 (pt)	2015-05-26	"composição fungicida, composto e método para controlar uma doença"
BRPI0817525A2 (pt)	2014-11-18	Composto, composição farmacêutica, e, metódo de tratamento, controle ou prevenção de uma doença ou distúrbio.
BRPI0818244A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0914405A2 (pt)	2015-08-11	"composto, composição fungicida e métodos para o controle de doenças de plantas"
BRPI0815591A2 (pt)	2015-03-03	Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0720637A2 (pt)	2014-04-15	Composto ou um sal farmaceuticamente aceitável, uma forma estereoisomérica, tautomérica ou polimórfica do mesmo, métodos para o tratamento de um hospedeiro e de tratamento de infecção, composição farmacêutica, e, uso do composto
BRPI0813311A2 (pt)	2014-12-23	Composto, métodos para modulara a atividade de uma proteína quinase e para tratar câncer em um indivíduo, e, composição farmacêutica.
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0922566A2 (pt)	2017-03-28	polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença.
BRPI1013984A2 (pt)	2018-06-19	composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BRPI0910734A2 (pt)	2015-09-29	composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo.
BRPI0917458A2 (pt)	2015-12-01	composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0819799A2 (pt)	2015-05-26	Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BRPI1013763A2 (pt)	2015-08-25	Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto
BRPI0923217A2 (pt)	2017-05-23	processos para a preparação de um composto de piridona, e para a preparação de uma forma cristalina, composto, sal ou um hidrato deste, forma cristalina de um sal de sódio ou um hidrato deste, e, composição farmacêutica.
BRPI0907976A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças

Legal Events

Date	Code	Title	Description
2014-08-26	B08L	Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]	Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 6A E 7A ANUIDADES.
2020-11-10	B08I	Publication cancelled [chapter 8.9 patent gazette]	Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA.
2020-11-17	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADES.
2021-03-09	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.